DNLI
Denali Therapeutics Inc

1,743
Mkt Cap
$2.95B
Volume
615,942.00
52W High
$26.18
52W Low
$10.57
PE Ratio
-6.91
DNLI Fundamentals
Price
$20.08
Prev Close
$20.11
Open
$20.36
50D MA
$16.44
Beta
1.61
Avg. Volume
1.44M
EPS (Annual)
-$2.57
P/B
3.18
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Denali Enters Into a $275M Funding Deal With Royalty Pharma
DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.
Zacks·2h ago
News Placeholder
More News
News Placeholder
Schroder Investment Management Group Purchases 94,744 Shares of Denali Therapeutics Inc. $DNLI
Schroder Investment Management Group increased its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 32.5% during the 2nd quarter, according to the company in its most...
MarketBeat·5h ago
News Placeholder
Schroder Investment Management Group Purchases 94,744 Shares of Denali Therapeutics Inc. $DNLI
Schroder Investment Management Group increased its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 32.5% during the 2nd quarter, according to the company in its most...
MarketBeat·5h ago
News Placeholder
Schroder Investment Management Group Purchases 94,744 Shares of Denali Therapeutics Inc. $DNLI
Schroder Investment Management Group increased its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 32.5% during the 2nd quarter, according to the company in its most...
MarketBeat·5h ago
News Placeholder
Schroder Investment Management Group Purchases 94,744 Shares of Denali Therapeutics Inc. $DNLI
Schroder Investment Management Group increased its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 32.5% during the 2nd quarter, according to the company in its most...
MarketBeat·5h ago
News Placeholder
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of "Buy" from Brokerages
Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has been assigned a consensus recommendation of "Buy" from the sixteen ratings firms that are currently covering the stock, MarketBeat.com...
MarketBeat·4d ago
News Placeholder
Groupama Asset Managment Buys 31,043 Shares of Denali Therapeutics Inc. $DNLI
Groupama Asset Managment grew its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 21.5% in the second quarter, according to the company in its most recent 13F filing with the...
MarketBeat·5d ago
News Placeholder
Bank of New York Mellon Corp Has $11.06 Million Holdings in Denali Therapeutics Inc. $DNLI
Bank of New York Mellon Corp decreased its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 28.4% during the second quarter, according to the company in its most recent...
MarketBeat·15d ago
News Placeholder
B. Riley Has Optimistic Outlook of DNLI FY2025 Earnings
Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - B. Riley lifted their FY2025 earnings per share estimates for shares of Denali Therapeutics in a report issued on Thursday, November 13th. B...
MarketBeat·18d ago
News Placeholder
Denali Therapeutics (NASDAQ:DNLI) Trading 8.8% Higher - Here's Why
Denali Therapeutics (NASDAQ:DNLI) Shares Up 8.8% - Here's What Happened...
MarketBeat·23d ago

Latest DNLI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.